A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus Infections
In brief
The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.
Key facts
- Study ID
- NCT02114268
- Run by
- MedImmune LLC
- People needed
- 342
- Starts
- 2014-04-01
- Expected to finish
- 2015-06-01
- Last updated by the study team
- 2016-11-28
Who can join
Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.